Kinfo
BioCryst Pharmaceuticals Inc. logo

BioCryst Pharmaceuticals Inc.

BCRXNASDAQHealthcare·US · USD
$10.45
-0.27 (-2.52%)
Prices as of July 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap2.65B USD
Enterprise value3.44B USD
Trailing P/E7.05
Forward P/E11.69
PEG ratio-0.00
Price / sales3.10
Price / book-4.57
Profitability
Gross margin96.56%
Operating margin-2.45%
Profit margin-51.71%
Return on assets42.62%
Return on equity-221.45%
Income (TTM)
Revenue885.72M USD
Gross profit678.70M USD
EBITDA365.14M USD
Net income-457.98M USD
Diluted EPS-$1.77
Rev. growth (YoY)7.50%
Balance sheet
Total cash238.40M USD
Total debt858.08M USD
Debt / equity-1.55
Current ratio1.91
Book value / share-$2.18
Cash flow (TTM)
Operating cash flow313.10M USD
Levered free cash flow264.38M USD
Shares & price
Shares outstanding254.01M
Float221.04M
Held by institutions101.17%
Beta0.54
50-day MA$9.07
200-day MA$8.05
52-week high$11.22
52-week low$6.00
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Monthly
Recent payments
  • 2014-06-11$0.00
Earnings (EPS)
DateEst.ActualSurprise2026-07-090.04-0.02−150.00%2026-05-060.110.14+27.27%2026-02-260.070.21+200.00%2025-11-2014.8314.73−0.67%2025-11-030.070.16+128.57%
About BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc. is a biotechnology company specializing in the research, development, and commercialization of novel small-molecule drugs that target key enzymes in infectious and inflammatory diseases. Leveraging expertise in biology, computer modeling, and medicinal chemistry, the company focuses on structure-guided drug design to create oral therapeutics for difficult-to-treat rare diseases. Its pipeline and products address critical therapeutic areas, including hereditary angioedema, acute and uncomplicated seasonal influenza, filoviruses such as Ebola and Marburg viruses, and oncology. BioCryst Pharmaceuticals Inc. operates within the healthcare sector, particularly in drug manufacturing for specialty and generic applications, contributing to treatments for rare conditions and emerging infectious threats. Founded in 1986 and headquartered in Durham, North Carolina, it plays a vital role in advancing innovative therapies for underserved patient populations in the biopharmaceutical market.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Charles K. Gayer
Employees
435
Headquarters
Durham, NC, United States

Frequently asked questions about BioCryst Pharmaceuticals Inc.